Walter Bianco an Arizona man denied access to new drugs to cure his hepatitis C infection will get the costly medications after all After NPR and Kaiser Health News   his plight on Monday federal Medicare officials said they would investigate Biancos appeal of an earlier denial had been rejected by WellCare a private insurer that contracts with the federal program to provide drug coverage Late Tuesday Biancos doctor got word that the earlier denials had been reversed I am very pleased that Mr Bianco received approval for the treatment he needs said   of Mayo Clinic in Scottsdale Ariz Biancos physician I hope all patients in similar or more urgent circumstances can be given a fair hearing Bianco whose liver has been severely damaged by the hepatitis C virus says Medicares reversal is great news for me and hopefully for many others since a precedent has been set now  Sean Cavanaugh deputy administrator of the   told NPR Widelyaccepted treatment guidelines for Hepatitis C have recently been updated and it is our understanding that the Part D plan decided to overturn its denial of a particular Hepatitis C treatment based on guidance that was not available at the time of the initial decision But its not clear whether Biancos case does indeed set a precedent Cavanaugh recently   that the agency is awaiting advice on how best to use the drugs and which patients should get them first Medicare officials have reportedly been consulting with the   and the   Both groups have recommended the use of the new drugs for patients like Bianco whose livers are heavily damaged by the virus but who are not yet at the end stage of infection  liver failure or liver cancer For now Medicares Part D contractors may decide on a casebycase basis whether to approve payment for the costly new drugs One of them called   costs  for a typical week course of treatment The other   costs about  The issue in the case of Bianco and thousands of others is whether Medicare will pay for their combined use  something not yet approved by the Food and Drug Administration although Olysios manufacturer Janssen Therapeutics sought approval of the combination on May  Older hepatitis C drug regimens have not cured the infection in Bianco and many others And many also cannot tolerate their harsh side effects The issue of paying for the expensive new drugs which cure upwards of  percent of patients is being closely watched by patient advocates federal health and budget officials state   the Department of Veterans Affairs and   across the country All face billions of dollars in potential obligations to treat the  million to  million Americans infected by the deadly virus Cavanaugh says Medicare expects to know the potential cost burden of the new drugs by the end of this year The agency will have more information after it receives bids in the coming weeks from Part D drug plan contractors which will take the cost of the new treatments for the coming year into account The publication   has reported that Gilead Sciences maker of Sovaldi received  percent of the  billion firstquarter sales of the drug  a record for any new drug  from Medicare and private health insurers An additional  percent of sales came from Medicaid Medicare officials fast response in the Bianco case is an indication of the political sensitivity of rejecting lifesaving coverage based on drug costs We want to try to be as helpful as we can to get beneficiaries the drugs that they need a Medicare spokesman said earlier this week Or to put it the other way around no one wants to be the first to say that patients who need the drugs cant get them  or that hepatitis C has pushed the nation into explicit rationing of lifesaving care